All Tox In Focus volumes
Tox In Focus
|
Focused Clinical Reference
Vol. 21  ·  Heroin  ·  July 2026
HEROIN
6-MAM confirms heroin, and telling it apart from poppy seed and prescription opioids

Heroin (diacetylmorphine) is a Schedule I opioid that rapidly metabolizes to 6-monoacetylmorphine (6-MAM) and then morphine. Detecting 6-MAM is the specific marker of heroin use, but its short window means remote use may show only morphine, which overlaps with poppy seed and prescription opioids.1

Why This Matters Now

Illicit heroin is now frequently adulterated with fentanyl and fentanyl analogues, and increasingly xylazine, which raise overdose risk and are not detected by an opiate screen or by heroin-marker testing.2 A heroin-positive result should prompt consideration of these co-present adulterants.

⚠ Morphine and codeine positives are not specific to heroin; poppy seeds and prescribed opioids can produce them. Only 6-MAM confirms heroin, and its short window means its absence does not exclude heroin use.3
Clinical Presentation
INTOXICATION
Euphoria then sedation
Miosis
Respiratory depression
Analgesia
Overdose: CNS and respiratory depression, death
WITHDRAWAL
Onset within hours of last use
Anxiety, agitation
Myalgia, GI upset
Rhinorrhea, lacrimation, yawning
Craving
Important: Illicit heroin commonly contains fentanyl and may contain xylazine; xylazine is not reversed by naloxone. A heroin-positive sample warrants attention to these adulterants.
UDT Considerations

LC-MS/MS measures 6-MAM, morphine, and codeine. 6-MAM with morphine (with or without codeine) indicates heroin use; because 6-MAM clears within about a day, remote heroin use may show only morphine, or morphine and codeine.3 Poppy seed ingestion and legitimate morphine or codeine use can also produce morphine and codeine positives, so interpret the pattern carefully.4

Clinical Guidance
  • Treat 6-MAM as the specific confirmation of heroin use.3
  • Do not exclude heroin on a 6-MAM negative; its window is short (~24 h).3
  • Distinguish poppy seed and prescription opioids when only morphine or codeine is present.4
  • Test for fentanyl and xylazine separately; heroin markers do not detect them.
  • Use the analyte-pattern grid to guide interpretation.
Point-of-Care Testing Availability
Available strips
Opiate immunoassays detect morphine and codeine but not 6-MAM specifically.
Clinical use
They do not detect fentanyl, a common heroin adulterant.
Limitations
LC-MS/MS measures 6-MAM, morphine, and codeine to confirm heroin.
HEROIN  |  Clinical & Program Guidance
Tox In Focus Vol. 21  ·  July 2026  ·  Page 2 of 2
Interpreting the Test Result
▲  If Testing Is Positive

6-MAM confirms heroin. Its presence is specific; its short window means absence does not exclude heroin.3

Morphine/codeine are not specific. Poppy seed and prescription opioids can cause them; use the pattern grid.4

Consider adulterants. Fentanyl and xylazine often accompany heroin and need separate testing.

Analyte Pattern Interpretation
6-MAMMorphineCodeineInterpretation
PosPos+/-Heroin use confirmed.
PosNegNegConsistent with heroin; interpret with caution.
NegPosPosNot confirmed; heroin, poppy seed, or codeine use.
NegPosNegMorphine source: remote heroin, morphine, or poppy seed.
NegNegPosCodeine: prescription codeine or heroin contaminant.

6-MAM is the specific heroin marker but clears within ~24 h; morphine or codeine alone are not specific to heroin (poppy seed, prescription opioids).

Key References
  1. Knight J, et al. Prevalence of heroin markers in urine for pain management patients. Forensic Sci Int. 2014;243:79-83.
  2. Centers for Disease Control and Prevention. Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities. 2015.
  3. White RM, Black ML. Pain Management Testing Reference. AACC Press; 2007.
  4. Concheiro M, et al. Morphine and codeine in oral fluid after controlled poppy seed administration. Drug Test Anal. 2015;7(7):586-591.
DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings.  |   © 2026 ToxiPharm LLC  |  toxipharm.org
Back to Tox In Focus ToxiPharm home →